Research Use Only - Not for human consumption. 18+ only.
Clinical TrialsGrowth Hormone SecretagoguesOral

Anamorelin

Also known as: RC-1291, Anavex

An oral ghrelin receptor agonist approved in Japan for cancer cachexia. Stimulates appetite and increases lean body mass in wasting conditions.

Research Status

Clinical Trials

Moderate Clinical Data

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Increases appetite and food intake
Improves lean body mass in cachexia
Enhances body weight in wasting conditions
Stimulates growth hormone secretion
Improves physical function in cancer patients
Reduces muscle wasting progression

Side Effects

Increased appetite and food intake
CommonMild

Intended therapeutic effect in cachexia; may cause weight gain if caloric intake exceeds expenditure in non-cachectic individuals.

Nausea
CommonMild

Often transient and may diminish with continued use. Taking with food may reduce incidence.

Headache
UncommonMild

Reported in clinical trials; typically mild and self-resolving.

Dizziness or lightheadedness
UncommonMild

May occur early in treatment; advise caution with position changes.

Elevated cortisol levels
UncommonModerate

Ghrelin agonism may transiently increase cortisol; monitor in patients with adrenal or metabolic concerns.

Fluid retention
UncommonMild

GH-mediated effects; typically mild and reversible upon discontinuation.

Hyperglycemia or impaired glucose tolerance
UncommonModerate

GH is diabetogenic; monitor blood glucose in patients with diabetes or prediabetes.

Abdominal discomfort or cramping
UncommonMild

Related to increased appetite and food intake; usually resolves with dose adjustment.

Fatigue
RareMild

Reported infrequently in clinical trials.

Cardiac arrhythmias or palpitations
RareSerious

Ghrelin agonists may affect cardiac function; contraindicated in patients with uncontrolled arrhythmias or acute cardiac disease. Requires medical evaluation if occurs.

Dosing Reference

ParameterValue
Dose range50-100 mg
Frequency1x daily
TimingBefore first meal
RouteOral

Oral administration. Approved in Japan for cancer cachexia. Start at 50 mg daily; may increase to 100 mg based on tolerance and response. For research purposes only.

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2–8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Molecular weight389.52
Half-life3-5 hours (oral)
SequenceC₂₀H₂₇N₃O₃S (non-peptide small molecule)

Anamorelin is a selective ghrelin receptor (growth hormone secretagogue receptor 1a) agonist that mimics the action of endogenous ghrelin. It stimulates growth hormone release from the anterior pituitary and increases appetite signaling in the hypothalamus, leading to increased food intake and preservation of lean body mass in catabolic states such as cancer cachexia.

Ghrelin Receptor Agonism (GHSR-1a)

Anamorelin binds to and activates the ghrelin receptor on somatotroph cells in the anterior pituitary, directly stimulating growth hormone secretion and appetite-regulating neurons in the hypothalamus.

Growth Hormone Axis

Increased GH secretion promotes protein synthesis, reduces protein catabolism, and enhances lipolysis, counteracting the metabolic derangements of cancer cachexia.

Appetite Stimulation

Activation of orexigenic pathways in the hypothalamus increases hunger signals and food-seeking behavior, improving nutritional intake in patients with reduced appetite.

  • Anamorelin is a non-peptide small molecule, not a peptide, but functions as a ghrelin mimetic
  • Oral bioavailability is approximately 60-70% with peak plasma levels 1-2 hours post-dose
  • Selective for GHSR-1a with minimal off-target receptor binding
  • Effects on GH secretion are dose-dependent and sustained with daily dosing

Track your Anamorelin research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Anamorelin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.